TWD 60.7
(-2.72%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - TWD | -100.0% |
2022 | 16.95 Million TWD | 0.0% |
2021 | - TWD | -100.0% |
2020 | 4.41 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | - TWD | 0.0% |
2024 Q2 | 1.93 Million TWD | 0.0% |
2023 Q4 | - TWD | -100.0% |
2023 Q3 | 1.14 Million TWD | -49.89% |
2023 FY | - TWD | -100.0% |
2023 Q2 | 2.28 Million TWD | -33.23% |
2023 Q1 | 3.42 Million TWD | 0.0% |
2022 Q4 | - TWD | 0.0% |
2022 FY | 16.95 Million TWD | 0.0% |
2021 FY | - TWD | -100.0% |
2020 FY | 4.41 Million TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Allied Biotech Corporation | 72.02 Million TWD | 100.0% |
GeneFerm Biotechnology Co., Ltd. | 76.14 Million TWD | 100.0% |
Easywell Biomedicals, Inc. | 330.44 Million TWD | 100.0% |
TTY Biopharm Company Limited | 403.04 Million TWD | 100.0% |
Synmosa Biopharma Corporation | 1.45 Billion TWD | 100.0% |
Orient EuroPharma Co., Ltd. | 2.2 Billion TWD | 100.0% |
Center Laboratories, Inc. | 4.42 Billion TWD | 100.0% |
Tien Liang BioTech Co., Ltd. | 377 Thousand TWD | 100.0% |
Orient Pharma Co., Ltd. | 323.73 Million TWD | 100.0% |
InnoPharmax Inc. | 5.38 Million TWD | 100.0% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 100.83 Million TWD | 100.0% |
Excelsior Biopharma Inc. | 300.25 Million TWD | 100.0% |
DV Biomed Co., Ltd. | 315.74 Million TWD | 100.0% |
Foresee Pharmaceuticals Co., Ltd. | 13.11 Million TWD | 100.0% |
Handa Pharmaceuticals, Inc. | 7.67 Million TWD | 100.0% |
UniPharma Co., Ltd. | - TWD | NaN% |
Anxo Pharmaceutical Co., Ltd. | 499.69 Million TWD | 100.0% |
Alar Pharmaceuticals Inc. | 138 Thousand TWD | 100.0% |
Winston Medical Supply Co., Ltd. | 56.05 Million TWD | 100.0% |
Mercury Biopharmaceutical Corporation | 41.66 Million TWD | 100.0% |
Bioray Biotech Co., Ltd | 65.65 Million TWD | 100.0% |